论文部分内容阅读
目的 探讨多药耐药基因(MDR1)和多药耐药相关蛋白基因(MDRP)在非小细胞肺癌(NSCLC)中的表达及意义。方法 采用逆转录多聚酶链反应(RTPCR),对33例NSCLC组织及相应癌旁组织中MDR1和MDRP基因表达进行检测。结果 癌组织中MDR1和MDRP阳性率(分别为69.7%和63.6%)明显高于癌旁组织(36.4%和30.3%,P<0.01);两基因的表达水平也显著高于癌旁肺组织(P<0.001,P<0.01);术前化疗者的MDR1和MDRP基因表达水平明显高于未化疗者(P<0.05)。结论 NSCLC具有内源性和获得性耐药性,检测MDR1和MDRP基因表达可指导临床化疗,并预测预后。
Objective To investigate the expression and significance of multidrug resistance gene (MDR1) and multidrug resistance-associated protein gene (MDRP) in non-small cell lung cancer (NSCLC). Methods Reverse transcriptional polymerase chain reaction (RTPCR) was used to detect the expression of MDR1 and MDRP genes in 33 cases of NSCLC tissues and their adjacent tissues. Results The positive rates of MDR1 and MDRP in cancer tissues (69.7% and 63.6%, respectively) were significantly higher than those in adjacent tissues (36.4% and 30.3%, P<0.01). The expression levels of the two genes were also significantly higher than those in adjacent lung tissues ( P <0.001, P <0.01); preoperative chemotherapy of MDR1 and MDRP gene expression levels were significantly higher than those without chemotherapy (P <0.05). Conclusion NSCLC has endogenous and acquired drug resistance. Detection of MDR1 and MDRP gene expression can guide clinical chemotherapy and predict prognosis.